SGO 2024 Insights: "COMB1NE Study - Characteristics and Real-World Outcomes of Epithelial Ovarian Cancer Patients Who Received Niraparib + Bevacizumab 1L Maintenance Therapy"

0 views
April 30, 2024
Comments 0
Login to view comments. Click here to Login